All eyes on Eli Lilly's anti-clotting drug candidate

09/30/2008 | The RPM Report/RPM First Take

Eli Lilly and Co.'s anti-clotting drug prasugrel, or Effient, is one of the most-watched drugs in the FDA approval pipeline, The RPM Report writes. Given its significant side effects and the company's efforts to get it on the market before the 2011 arrival of Plavix generics, investors are watching to see how the FDA will use its new risk management authority. The big question is whether the drug's bleeding risk can be appropriately managed or if FDA will require more assurances.

View Full Article in:

The RPM Report/RPM First Take

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX